


PROGRAM

1st December 2025



08:15 – 8:40 **Participant check-in & Welcome Coffee**

08:45 **Welcoming address** Remy Genthon and Isabelle Le Ber

09:00 – 10:45 **Session 1. Chairs : E. Buratti & A. Schneider**

09:00 ICGEB in biomarker analyses | [Emanuele Buratti](#) / Francesca Parron

09:15 Mapping the road from FTD fluid biomarker development to mechanistic insight | [Steffi de Meyer](#) / Vera Wiersma

09:30 NULISA-seq in the DZNE DESCRIBE FTD cohort | Anja Schneider

09:45 Tau-Proteins in blood in TDP43 diseases | [Markus Otto](#) / Arthur Guthknecht

10:00 Olfactory mucosa involvement in genetic FTD-TDP | Gianluigi Zanusso

10:15 CSF TDP-43 Seeding Activity across presymptomatic and symptomatic FTD/ALS stages | Paola Caroppo / [Vittoria Aprea](#)

10:30 TDP-43 Seed amplification assay | Fabio Moda / [Merve Begum Bacinoglu](#)

10:45 **COFFEE BREAK**

11:00 – 12:30 **Session 2. Chairs : M. Neumann & DM Thal**

11:00 Mapping the molecular trajectory in patients; from clinic to pathology | [Yolande Pijnenburg](#) / Anke Dijkstra

11:15 LATE-NC and its interactions with Alzheimer's disease | [Dietmar Rudolf Thal](#) / Sandra O. Tomé

11:30 Protein profiles of TDP-43 pathology in the brain and spinal cord | Emily Feneberg

11:45 Neuropathological subtypes of TDP-proteinopathies | Manuela Neumann

12:00 Is TDP-43 pathology in MND affected by intensive physical activity? | Claire Troakes / [Jaimee Kennedy](#)

12:15 Alzheimer's disease co-pathology vs. TDP43: contribution to cognitive impairment in ALS | [Andreas Hermann](#) / Anze Karlek

12:30 – 13:20 **Lunch Break**

13:30 – 15:00 **Session 3. Chairs : M. Hallegger & P. Fratta**

13:30 Decoding the molecular role of TDP-43 condensation in neurodegeneration using transcriptomics and biophysics | [Martina Hallegger](#) / Andrea Giuliani / [Félicie Lorenc](#)

13:45 Molecular dose-dependant effects of TDP-43 loss | [Pietro Fratta](#) / Auri Zbinden

14:00 Exploring m5C RNA Methylation in ALS Pathogenesis | Ludo Van Den Bosch / [Marcello Giunta](#)

14:15 hnRNP networks | Tammaryn Lashley / [Ariana Gatt](#)

14:30 Dysregulation of RNA processing in TDP43 proteinopathies | [Akshay Bhinge](#) / Aileen Zhang

14:45 TDP-43 gain of toxic function impacts splicing in neurodegeneration | [Eran Hornstein](#) / Thea Meimoun

15:00 **COFFEE BREAK**

15:15 – 16:30 **Session 4. Chairs : P. Van Damme & A. Isaacs**

15:15 Understanding motor neuron dysfunction induced by TARDBP mutations using iPSC-derived human motor neurons | Philip Van Damme / [Jimmy Beckers](#)

15:30 Changes in TDP-43 during aging and their impact on locomotor decline | Fabian Feiguin

15:45 TMEM106B modulates neuroinflammation in TDP-43 mouse model | Dieter Edbauer

16:00 Progranulin deficiency triggers microglial degeneration and accelerates neuropathology | [Renzo Mancusa](#) / Anne Wienand

16:15 Loss of TDP-43 causes widespread lipidomic changes in iPSC-neurons | Adrian Isaacs / [Alex Cammack](#)

16:30 **TEA TIME**

17:00 – 17:45 **Session 5. Chairs : E. Buratti & I. Le Ber**

17:00 Novel digital measures in C9orf72-related FTD/ALS | [Rhian Convery](#) / [Phoebe Foster](#)

17:15 VectorY Therapeutic targeting of TDP-43 using intrabodies | Sander van Deventer

17:30 Golgi Neurosciences: Development of small molecules able to correct Stathmin-2 splicing and TDP43 mis-localization for ALS and other TDP-43-mediated neurodegenerative diseases | Chiara Liberati / Stefan Lohmer


17:45 – 18:45 **Round table – Chairs: M. Benatar** How many entities to treat and how many therapies to develop?

Manuela Neumann / John van Swieten / Pietro Fratta / Sandrine Da Cruz / Rosa Rademakers / Chiara Liberati / Sander van Deventer

19:00 – 21:00 **Cocktail**

PROGRAM

2nd December 2025



08:30 – 08:55 Participant check-in & Welcome Coffee

09:00 – 10:00 Session 1. Chairs : R. Rademakers & I. Le Ber

- 09:00** Neuro-TDP-43 Disease: A framework for integrated staging | Michael Benatar
- 09:15** Genetic modifiers of TDP-43 proteinopathies | [Mathieu Barbier](#)/Isabelle Le Ber
- 09:30** FTLD-TDP Is Not One Disease: Multi-Omics Insights into Subtype-Specific Pathogenesis | [Rosa Rademakers](#)/Júlia Faura Llorens
- 09:45** Somatic TARDBP variants identified in the brain of FTD-TDP-C patients disrupt physiological TARDBP function in zebrafish | John van Swieten/[Ana Rajjic](#)

10:00 COFFEE BREAK

10:15 – 12:00 Session 2. Chairs : B. Ryskeldi-Falcon & D. Dormann

- 10:15** Molecular mechanisms driving aberrant condensation of TDP-43 | [Dorothee Dormann](#)/Simone Mosna
- 10:30** The role of stress granules in TDP-43 aggregation | Simon Alberti
- 10:45** Potential role of SUMOylation in TDP43 cellular trafficking and aggregation | Marco Feligioni
- 11:00** Phase Separation of TDP-43 and its Fragments in vitro and in cells | [Fabrizio Chiti](#)/Isabella Marzi
- 11:15** TDP-43 interactomics | Boris Rogelj/[Jerneja Nimac](#)
- 11:30** Bringing structure to pathological TDP-43 assembly | Benjamin Ryskeldi-Falcon
- 11:45** NMR Mapping of Early ANXA11-TDP-43 Recognition in Non-Assembled States | Miguel Mompeán/[Andrea Gelardo](#)

12:00 – 13:20 Lunch Break

13:30 – 15:00 Session 3. Chairs : S. Carra & M. Latouche

- 13:30** TDP-43 SUMO2/3-ylation prevents its irreversible aggregation | Serena Carra
- 13:45** Protein kinases inhibitors as modulators of TDP-43 pathology | [Ana Martinez](#)/Carmen Gil
- 14:00** Small molecule disaggregation of TDP-43 fibrils | Olivier Sperandio/[Zachariah Schuurs](#)
- 14:15** TDP-43 small molecules ligands | Morwena Latouche/[Lea El Hajjar](#)
- 14:30** ALS Therapeutics by AAV-delivery of scFv against TDP-43 | Helene Blasco/[Yara Alojaimi](#)
- 14:45** Leveraging aberrant splicing in ALS for new therapeutic approaches | [Oscar Wilkins](#)/Max Chien

15:00 COFFEE BREAK

15:15 – 16:45 Session 4. Chairs : S. Mizielska & M. Polymenidou

- 15:15** Molecular determinants of cytoplasmic TDP-43 toxicity | [Sarah Mizielska](#)/Seoungjun Lee
- 15:30** Muscle-Exosome Control TDP-43 Local Synthesis at the NMJ | Eran Perlson
- 15:45** Mitochondrial and synaptic dysfunction in TDP-43 iPS-derived motor neurons | [Ruxandra Dafinca](#)/Delphi MacWhite-Begg
- 16:00** Synaptopathy in TDP-43 models | Emma Clayton/[Laura Huggan](#)
- 16:15** Exploring the converging toxic mechanisms of TDP-43 aggregation and loss of function | [Magdalini Polymenidou](#)/Ruchi Manglunia
- 16:30** Uncovering local mechanisms of axon/synapse maintenance and loss in ALS/FTD | Sandrine Da Cruz/[Bilal Khalil](#)/[Catarina Costa Da Gloria](#)

16:45 Closing remarks Morwena Latouche